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Abstract Gastric MALT lymphoma is closely associated
with Helicobacter pylori infection. Bacterial eradication ther-
apy comprising clarithromycin is the first-line treatment in
gastric MALT lymphoma patients. However, antimicrobial
resistance to clarithromycin has been increasing in Europe,
and thus far, it has not been examined in gastric MALT lym-
phoma patients. Based upon histopathological investigation,
17 adult gastric MALT lymphoma patients were identified to
be related with H. pylori infection between 1997 and 2014.
Detection of H. pylori infection in these patients and
clarithromycin susceptibility testing were performed by 23S
rRNA gene real-time PCR. Twelve of the patients were con-
firmed with H. pylori infection by real-time PCR. Among
these patients, only two were found to be infected with
clarithromycin-resistant H. pylori strain. In one of them, both
the clarithromycin-resistant and sensitive genotype were de-
tected. The rate of clarithromycin resistance was 15.4 %.
Clarithromycin resistance pattern in gastric MALT lymphoma
patients is under the predictions since a previous study per-
formed in Central Europe revealed a rate of 36.6 % in Austria.
Considering the low antimicrobial resistance rate,
clarithromycin is still an option in gastric MALT lymphoma
management.
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Introduction
Extranodal marginal zone lymphoma of mucosa-associated
lymphoid tissue (MALT) lymphoma most commonly affects
the stomach where it accounts for almost 50 % of all gastric
lymphomas [1–3]. Still, gastric MALT lymphoma is a rare
disease and therapeutic recommendations are mostly based
on retrospective data and clinical experience, while only few
randomized controlled data are available [4].
Current evidence strongly supports a causal role of
Helicobacter pylori infection in the evolution of the disease,
and antibiotic treatment is the therapeutic mainstay of man-
agement of such patients. In almost 90 % of cases, gastric
MALT lymphoma is thought to be associated with infection
with this microaerophilic, Gram-negative bacterium, although
recent studies have shown a much higher rate of H. pylori-
negative patients [4–6]. We could confirm recently this trend
in an Austrian cohort by observing a rate ofH. pylori-negative
cases of MALT lymphoma of 32 % [7]. Still, patients with
gastric MALT lymphoma are significantly more likely to have
evidence of previousH. pylori infection thanmatched controls
[8]. Eradication of H. pylori infection is associated with re-
gression of gastric MALT lymphoma in the large majority of
patients and has been reported to be beneficial even in patients
without laboratory confirmation of H. pylori infection [3, 7,
9]. The most widely accepted hypothesis for the pathogenesis
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of gastric MALT lymphoma states accordingly that H. pylori
infection of the stomach indirectly stimulates B cells by acti-
vation of CD4+ T cells and also CagA is translated into lym-
phoma cells [10, 11]. Consecutively, a chronic activation of B
cells and local inflammation with the generation of free reac-
tive oxygen species triggers the evolution of gastric MALT
lymphoma [11].
Accordingly, H. pylori eradication is recommended by all
current international guidelines as first-line treatment for pa-
tients suffering from gastric MALT lymphoma, irrespective of
stage [2, 3, 12]. The standard treatment regimen recommend-
ed forH. pylori eradication consists of a clarithromycin-based
triple therapy, also including a proton pump inhibitor (PPI)
twice a day and amoxicillin or metronidazole for 7 or 14 days
[3]. Nevertheless, antimicrobial resistance rates have been in-
creasing dramatically in clinical H. pylori strains. In Europe,
resistance rates to the key antimicrobial clarithromycin range
between 5.6 and 36.6 %, with Austria leading the table [13].
Evaluation of clinical H. pylori strains for antimicrobial resis-
tance is recommended for patients with treatment failures, as
well as those originating from geographic regions with high
rates of antimicrobial resistance [4]. However, in gastric
MALT lymphoma patients, bacterial culture has a clearly low-
er sensitivity than histology even if performed under opti-
mized conditions [14], thereby limiting the utility of data re-
garding antimicrobial resistance. As a consequence, the opti-
mum antimicrobial combination treatment in gastric MALT
lymphoma patients from geographic regions with high resis-
tance rates remains yet to be defined.
In this study, we therefore evaluated genotypic
clarithromycin resistance rates of clinical H. pylori strains in
a cohort of gastricMALT lymphoma patients through utilizing
a highly sensitive and reliable real-time PCR assay. We found
that clarithromycin resistance rates are clearly lower in gastric
MALT lymphoma patients than anticipated from epidemio-
logical information in the general population.
Materials and Methods
Patients Patients eligible for this retrospective, monocentric
analysis had a histological confirmation of gastricMALT lym-
phoma diagnosed between January 1997 and December 2014.
In addition, only gastric biopsy samples that were histologi-
cally positive for Helicobacter-like organisms (HLO) were
included in the present study. The presence of H. pylori could
be further confirmed with use of VENTANA anti-H. pylori
(SP48) rabbit monoclonal primary antibody (Roche
Diagnostics, Basel, Switzerland). Only cases with sufficient
archived primary tumour tissue were selected. Demographic
and clinical data were collected retrospectively from patients’
notes and prescription charts. The study was performed in
accordance with the Declaration of Helsinki and good clinical
practice guidelines and was approved by the local ethics com-
mittee (EK1548/2014). Informed consent was obtained for the
diagnostic procedures from all individual participants includ-
ed in the study.
DNA purification Genomic DNAwas extracted from repre-
sentative formalin-fixed, paraffin-embedded tissue blocks of
biopsy samples collected from gastric MALT lymphoma pa-
tients. DNAwas purified using an EZ1 DNATissue kit (No.
953034; Qiagen, Hilden, Germany) according to the tissue
protocol followed by automated purification using the EZ1
instrument.
Microbiological evaluation All HLO-positive biopsy sam-
ples available from the present gastric MALT lymphoma pa-
tients were tested for the presence of H. pylori-specific DNA
with use of a previously described assay [15]. In brief, this
PCR assay amplifies a H. pylori DNA fragment of 137 bp of
the 23S rRNA gene including the sites of mutation that confer
phenotypic resistance to clarithromycin. Isolated DNA was
subjected to 70 amplification cycles (with a temperature tran-
sition rate of 20 °C/s) of denaturation at 95 °C for 5 s, anneal-
ing at 65 °C for 10 s, and primer extension at 72 °C for 6 s. The
limit of detection of this PCR assay for pure H. pylori DNA
was 4 fg per PCR, which is equivalent to 2.2 bacteria and
H. pylori specificity and sensitivity of this PCR assay was
confirmed to be 98 and 100 %, respectively. Genotypic
clarithromycin resistance of clinicalH. pylori strains was eval-
uated with use of melting point analysis performed after the
amplification of the 23S rRNA gene as described previously.
For this purpose, a probe binding to the site of mutations in the
23S rRNA gene was used during amplification. Melting tem-
peratures were analysed for significant differences to the wild-
type H. pylori genotype (the melting temperature is lower in
mutated strains than in wild type, clarithromycin-sensitive
strains because of the mismatch between the amplicon and
the probe, which corresponds to the wild-type susceptible ge-
notype). Every PCR run included several positive and nega-
tive controls. As positive controls, DNA samples extracted
from pure clarithromycin-sensitive and resistant H. pylori iso-
lates were used. As negative control, master mix solution
filled up with water to the final volume was applied.
PCR amplification of the cagA variable region was per-
formed as previously described by using the primers and con-
ditions with some modifications [16]. Primers were modified
to account for the mismatches at primer binding sites among
the different H. pylori cagA genotypes available through
GenBank (Table 1). Alignment of sequences was done using
CLC Genomics Workbench Software (CLC bio, QIAGEN,
Hilden, Germany). First screening of samples was done with
use of the EPIYA PCR using the forward primer CagA-Tfw
and three reverse primers (CagA-rvP1, CagA-rvP2, and
CagA-rvP3) to amplify the three different EPIYA sites of the
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cagA gene, P1, P2, and P3, and thereby determine the EPIYA
motifs encoded. To exclude a low sensitivity of this PCR
assay as possible explanation for negative test results, a sec-
ond cagA-specific PCR that amplifies the entire 3′ repeat re-
gions of the cagA gene was performed using the forward
primer CagA-Tfw and reverse primer CagA-Trv. In present
study, iProof DNA polymerase (Bio-Rad Laboratories,
Hercules, CA) was used, which has the 3′ to 5′ exonuclease
proofreading activity and may be more accurate than Taq po-
lymerase. A reaction mixture containing 0.2 mM of each
deoxynucleoside triphosphate, 3 mM MgCl2, 0.5 μM of both
forward and reverse primers, 3 % DMSO, 0.02 U of iProof
DNA polymerase/μl, 1× iProof HF Buffer (Bio-Rad
Laboratories, Hercules, CA), and 1 μl of DNA was used.
The mixture was incubated at 98 °C for 30 s, followed by
35 cycles at 98 °C for 10 s, 57 °C for 15 s, and 72 °C for
15 s, and a final extension at 72 °C for 5 min. The resulting
PCR products were analysed on 2 % agarose gel.
Results
From January 1997 to December 2014, a total of 97 patients
with gastric MALT lymphoma were evaluated and treated at
Vienna General Hospital, Austria as previously described [7].
A total of seven patients (7 %) had detectable HLO in gastric
biopsies at the time of evaluation. In one patient, HLO could
be detected in three samples collected over a period of 3 years.
In addition, we also evaluated gastric biopsy samples collect-
ed from additional ten patients who were treated at other in-
stitutions over the same period and whose samples were sent
to our institution for histological evaluation. HLO were de-
tected in all of these ten samples as well. The mean age (±SD)
of the 17 patients was 72±9 years (range, 57–88 years) and
71% (12 of 17) of themwere male. Remarkably, seven (41%)
of the 17MALT lymphoma patients received eradication ther-
apy for H. pylori before the present detection of HLO in their
gastric biopsies.
Histological evaluation further confirmed the presence of
signs of gastritis in all 19 gastric biopsy samples from the 17
patients. Semi-quantitative evaluation of HLO density in the
samples showed low density in eight, intermediate density in
six, and high density in five samples.
Isolation of DNA from formalin-fixed tissue samples and
testing with the H. pylori-specific PCR assay yielded positive
test results in 14 (74 %) of the 19 histologically HLO-positive
samples. These 14 H. pylori-positive samples were collected
from 13 different gastric MALT lymphoma patients. A false-
negative PCR result was not associated significantly with a
low HLO density in the gastric biopsy samples (4/8 vs 1/11;
P=0.111 [Fisher Exact]). Analysis of the 23S rRNA gene for
genotypic clarithromycin resistance revealed sensitive strains
in 11 (79 %) of the 14 samples. Clarithromycin-resistant
H. pylori strains could be detected only in two different sam-
ples from a single patient and in the sample from a further
patient, in which a mixed genotype was detected. The rate of
clarithromycin-resistant H. pylori infections was accordingly
15 % (2 of 13).
Follow-up studies revealed that H. pylori infection was
eradicated successfully in all five patients with information
available. Remarkably, the single patient with repeated detec-
tion of a clarithromycin-resistantH. pylori strain was eradicat-
ed successfully between these positive test results as indicated
by a negative histological evaluation of gastric biopsies. Upon
follow-up gastric biopsies, however, the patient’s samples
were again positive for H. pylori indicative for reinfection
by a clarithromycin-resistant H. pylori strain. Eight patients
were lost to follow-up due to gastrectomy (n=1), an addition-
al malignancy requiring immediate chemotherapy or rapid
progression of MALT lymphoma (n=3), or unknown reasons
(n=4).
In addition, we tested the gastric biopsy samples for the
presence of the cagA because H. pylori strains possessing that
gene are more likely to cause disease than those lacking it
[17–19]. All samples tested by EPIYA PCR were negative
for the cagA. To avoid a bias by a limited sensitivity of this
PCR, we tested all samples also with a more sensitive pan-
cagA PCR with the same results.
Discussion
Antimicrobial eradication treatment is the mainstay in the
management of gastric MALT lymphoma patients based on
the recognition of a likely causal role of H. pylori infection in
the evolution of the disease and excellent response rates to
antimicrobial combination treatment [7, 20]. H. pylori antimi-
crobial resistance rates, however, increased clearly in the last
decade with clarithromycin resistance rates as high as 37 %
[13]. Contrary to our initial expectation, we found that
clarithromycin resistance rates were as low as 15 % in the
present cohort of gastric MALT lymphoma patients which
suggests that clarithromycin is still an effective choice in the
empiric eradication of H. pylori infection.
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The standard antimicrobial regimen recommended for
H. pylori eradication in the general population as well as in
patients with gastric MALT lymphoma is based on a
clarithromycin-backbone substituted with a PPI and amoxicil-
lin or metronidazole for 7 or 14 days [3]. The increase in
antimicrobial resistance, particularly in Central Europe, re-
quired a switch to second-line regimens in empiric eradication
therapy [21]. Second-line treatments, however, are associated
with a higher pill burden, higher rates of adverse events, and
the risk to induce antimicrobial resistance in other infectious
pathogens. In view of the limited information available on
H. pylori antimicrobial resistance patterns in patients with
gastric MALT lymphoma, data from the general population
suggest that second-line regimens might also be required in
the case of these patients. Our analyses, however, reveal a
clarithromycin resistance rate as low as 15.4 %, which is
clearly lower than expected from the high resistance rate of
37 % observed previously in Austria. Although the present
observations have to be interpreted with caution due to the
small size of the cohort studied, first-line antimicrobial eradi-
cation regimens still appear to be effective options for empiric
treatment.
To determine the presence of H. pylori infection in gastric
MALT lymphoma patients, a combination of several diagnos-
tic techniques is advised by international guidelines, including
invasive (e.g., histology, rapid urease test, or bacterial culture)
and non-invasive techniques (e.g., serology and urea breath
test) [2]. Establishing the diagnosis of H. pylori infection in
gastric MALT lymphoma patients, however, may be difficult.
Results obtained through the use of histology, bacterial cul-
ture, PCR, and serology are concordant only in 63 % of cases
[14]. For the detection of H. pylori in gastric MALT lympho-
ma patients, bacterial culture of gastric biopsy samples was
found to be unsatisfactory, when the generally high sensitivity
of bacterial culture for the detection of infectious pathogens is
considered, in a diversity of clinical samples [14].
P reva lence of H. py lor i in fec t ion would be
underestimated if only one diagnostic tool would be used.
Still, we could identify HLO with use of histology only in
seven of 97 gastric biopsy samples. The very small num-
ber of gastric MALT lymphoma patients with detectable
HLO in their gastric biopsy samples requires explanation.
Information on the prevalence of HLO positivity in gastric
MALT lymphoma patients is still limited to a few case
series [14]. In a large European cohort study, histology
was positive for HLO in 29 of 90 patients with gastric
MALT lymphoma. The present retrospective study was
conducted at a tertiary hospital, and we may not exclude
selection biases deriving from previous eradication thera-
pies prescribed before referral, as well as a trend towards
evaluation and management of more advanced stages of
the disease [7]. Accordingly, it may currently be only
hypothesized on the true prevalence of H. pylori positivity
in gastric MALT lymphoma patients when direct diagnos-
tic assays are used.
The presence of H. pylori in gastric biopsy samples could
be confirmed by PCR in 74 % of samples that were HLO
positive by histology. The PCR assay used was thoroughly
evaluated and is highly sensitive [15] but, in the present study,
was used for the detection of H. pylori-specific DNA in for-
malin-fixed, paraffin-embedded tissue samples. Formalin
treatment also fragments DNA and traps it by extensive
cross-linking between nucleic acid strands [22]. Moreover,
the likelihood of a positive PCR assay did not correlate with
the density of H. pylori in the tissue samples, which points
rather to a technical than to a biological explanation for neg-
ative PCR results. DNA isolated from formalin-fixed,
paraffin-embedded tissue samples is, therefore, of poor quality
overall, and pose a major challenge for the detection of spe-
cific DNA targets.
Nevertheless, negative test results obtained with use of the
H. pylori-specific PCR assay may also be explained by infec-
tion with Helicobacter heilmannii. A minority of gastric
MALT lymphomas is associated with infection by
H. heilmannii, which is difficult to differentiate from
H. pylori when using standard stains in histology.
Nevertheless, we also evaluated PCR-negative tissue samples
with use of H. pylori-specific immunohistochemistry and
found that the HLO detected were actually H. pylori.
Accordingly, negative PCR results obtained from evaluation
of formalin-fixed, paraffin-embedded tissue samples have to
be interpreted with caution.
The evolution of gastric MALT lymphoma has been
related specifically to H. pylori strains expressing the
cag pathogenicity island, which is an important virulence
factor in this infection [17]. WHO and International
Agency for Research on Cancer define cagA as a human
class I carcinogen [23, 24]. Upon H. pylori infection,
CagA is translocated into gastric epithelial cells where it
deregulates intracellular signalling pathways and thereby
promotes lymphomagenesis [10]. H. pylori strains that do
not encode cagA were associated with resistance to met-
ronidazole, but not to clarithromycin [25–27]. CagA-spe-
cific antibodies are found in 89–96 % of sera from pa-
tients with gastric MALT lymphoma [18, 19]. In a previ-
ous study, the cagA gene was detected in 47 % of
H. pylori strains from gastric MALT lymphoma patients
[14]. In contrast, we were not able to identify a single
patient harbouring a cagA-encoding H. pylori strain. The
negative test results may again be attributable to the low
quality of DNA recovered from formalin-treated biopsy
samples. Still, we used two different and sensitive PCR
assays to avoid false-negative test results [28]. A signifi-
cant difference to the previous study, however, is the ma-
terial used; we used primary samples whereas cultured
bacteria were used in the previous study.
1118 Ann Hematol (2016) 95:1115–1120
In conclusion, the antimicrobial resistance to clarithromycin
in H. pylori strains obtained from gastric MALT lymphoma
patients is relatively low and clarithromycin is still a valid
choice in empiric eradication treatment. The presence of
clarithromycin-resistant H. pylori strains, however, should be
considered in patients with treatment failure.
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